Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04113915|
Recruitment Status : Not yet recruiting
First Posted : October 3, 2019
Last Update Posted : November 1, 2019
Aim of the work To estimate frequency of viral HB & C infection in ITP patients who received triple therapy in comparison with another group treated with steroids only.
To explore risk factors and routes of transmission of viral HB & C infection in ITP patients who received triple therapy and the another group treated with steroids .
- To assess preventive measures of viral HB& C infection in the hematology ward To investigate the influence of viral HB & C infection on clinical picture, response to treatment and side effects in ITP patients who received triple therapy or steroids.
|Condition or disease||Intervention/treatment|
|ITP - Immune Thrombocytopenic Purpura Viral Hepatitis||Drug: triple therapy Drug: Steroids|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Viral Hepatitis B and C Infection in Patients With Idiopathic Thrombocytopenic Purpura Treated With Triple Therapy|
|Estimated Study Start Date :||November 2019|
|Estimated Primary Completion Date :||November 2020|
|Estimated Study Completion Date :||December 2020|
Group of ITP patients received triple therapy
Drug: triple therapy
Effect of treatment on immunity to obtain infection with hepatitis B&C
Other Name: High dose dexamethasone together with cyclosporin and rituximab
Group of ITP patients received steroids
Oral or parenteral steroid therapy for ITP
Other Name: Parenteral decadrone or oral hostacortine
Normal control group
- To estimate frequency of viral HB & C infection in ITP patients who received triple therapy in comparison with another group treated with steroids and risk factors affecting infection [ Time Frame: 1 year ]
- 1-To assess preventive measures of viral HB& C infection in the hematology ward 2-to asses effect of viral hepatitis b,c on clinical picture , response to treatment and side effects in ITP patients received triple therapy [ Time Frame: 1year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04113915
|Contact: Safaa A Khaled, Ass. Prof.||01064170058 ext firstname.lastname@example.org|
|Contact: Shymaa Mohamed Nageeb, MD||01032165735||Shymaanageeb1993@gmail.com|
|Study Director:||Mohammad Elyamany, Prof.||Yamany1@yahoo.com|
|Principal Investigator:||Shymaa Mohamed Nageeb, MD||Shymaanageeb1993@gmail.com|